Frequencies of hprt mutant lymphocytes in smokers, non-smokers, and former smokers.
Previous work with the autoradiographic mutant lymphocyte assay has provided information about the time-course of development of hprt mutations and the persistence of detectable mutant cells in human subjects following therapeutic exposures to genotoxic agents. These early studies also revealed elevations in frequencies of mutant cells in pretreatment blood samples from patients who were current tobacco smokers, but no information was available on former smokers. In the present study, blood samples were obtained from 21 healthy former tobacco smokers who had quit smoking at least 1 year before sampling, 42 subjects who had never smoked, and 23 tobacco smokers. Plasma from all samples was tested for cotinine, a metabolite of nicotine. Current smokers were categorized as heavy smokers (> or = 10 cigarettes per day, cotinine > or = 90 ng/ml plasma) and light smokers (< 10/day, cotinine < 90 ng/ml). Lymphocytes from the blood samples were isolated, cryopreserved, and later thawed and assayed with the autoradiographic hprt assay. The 21 former tobacco smokers had a mean variant (mutant) frequency (Vf +/- standard error) of 1.97 (+/-0.13) per million evaluatable cells. The Vf of 42 subjects who had never smoked was 1.74 (+/-0.13) x 10(-6), not significantly different from the former smokers. The smokers had Vfs of 8.09 (+/-0.78) x 10(-6) for 18 heavy smokers and 5.22 (+/-1.02) x 10(-6) for five light smokers. The two categories of smokers had frequencies of mutant cells significantly different from each other, and each was significantly higher than non-smokers and former smokers (P < 0.05). Vfs were significantly correlated with both cotinine concentrations and the number of cigarettes smoked per day, P < 0.001. This study demonstrates the sensitivity of the autoradiographic hprt assay for detecting mutagenic effects related to chronic low-level exposures to genotoxins, and indicates that this assay is more likely to detect the effects of recent rather than past exposures.
Ammenheuser
M M
MM
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston 77555-1110, USA. marinel.ammenheuser@utmb.edu
Hastings
D A
DA
Whorton
E B
EB
Ward
J B
JB
D000293:Adolescent; D000328:Adult; D000368:Aged; D002188:Cannabis; D003367:Cotinine / Q000097:blood; D005260:Female; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000187:drug effects / Q000235:genetics*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009152:Mutagenicity Tests; D009154:Mutation; D010947:Plants, Toxic; D044469:Racial Groups; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation; D014026:Nicotiana
D007041:Hypoxanthine Phosphoribosyltransferase; D003367:Cotinine